(Q38017363)

27 August 2017

title

Low-molecular-weight heparin and survival in lung cancer (English)

1 reference

27 August 2017

1 reference

1 reference

1

Simon Noble

1 reference

27 August 2017

publication date

1 April 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

129 Suppl 1

1 reference

27 August 2017

page(s)

S114-8

1 reference

Estimates of the cancer incidence and mortality in Europe in 2006.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

The epidemiology of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Epidemiology of Lung Cancer*

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

The treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

The National Cancer Data Base report on lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Cancer survival in England and Wales at the end of the 20th century.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Clinical features of metastatic bone disease and risk of skeletal morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? An urgent call for research

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Deep vein thrombosis of the leg. Is there a "high risk" group?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Venous thromboembolism and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Epidemiology and pathophysiology of cancer-associated thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

The challenges of managing cancer related venous thromboembolism in the palliative care setting

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Factors influencing hospice thromboprophylaxis policy: a qualitative study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Prognosis of Cancers Associated with Venous Thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

The incidence of venous thromboembolism among patients with primary lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Haemostatic abnormalities in lung cancer: prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Activators of coagulation in cultured human lung-tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Mechanisms of disease: the impact of antithrombotic therapy in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Antithrombotic therapy and survival in patients with malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Development and validation of a predictive model for chemotherapy-associated thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

Heparin as an inhibitor of cancer progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970029-4

7 January 2021

10.1016/S0049-3848(12)70029-4

Identifiers

DOI

1 reference

27 August 2017

1 reference